TLR7 agonists include native ssRNAs and small molecules such as imidazoquinolines and benzazepines.7 Imidazoquinolines are structurally similar to the most-studied class of TLR7 agonist and include the Food and Drug Administration (FDA)-approved imiquimod and its more potent counterpart resiquimod (R848).8 Small-molecule TLR7 agonists already demonstrated success in dermatologic malignancies including basal cell carcinoma9, but will require further optimization for other types of cancer. This evidence concerns the gene TLR7 and cancer.